Detection of antibodies against SARS-CoV‑2
Development of an automated flow-based chemiluminescence microarray immunoassay (CL-MIA) for the detection of antibodies against SARS-CoV‑2 RBD/spike protein and N protein in human serum and plasma in less than 8 min with high specificity and sensitivity.
In the face of the COVID-19 pandemic, the need for rapid serological tests that allow multiplexing emerged, as antibody seropositivity can instruct about individual immunity after an infection with SARS-CoV‑2 or after vaccination. As many commercially available antibody tests are either time-consuming or tend to produce false negative or false positive results when only one antigen is considered, we developed an automated, flow-based chemiluminescence microarray immunoassay (CL-MIA) that allows for the detection of antibodies to SARS-CoV‑2 RBD/spike protein and N protein in human serum and plasma in less than 8 min. The CoVRapid CL-MIA was tested with SARS-CoV‑2 serology positive or negative samples, resulting in 100% diagnostic specificity and 100% diagnostic sensitivity, thus outcompeting other commercial tests run on the same sample set.
Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV‑2 in human serum and plasma (CoVRapid CL-MIA)
Klüpfel J, Koros RC, Dehne K, Ungerer M, Würstle S, Mautner J, Feuerherd M, Protzer U, Hayden O, Elsner M, Seidel M. Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV‑2 in human serum and plasma (CoVRapid CL-MIA). Anal Bioanal Chem. 2021:1–14. doi: 10.1007/s00216-021–03315‑6.
Richardson et al., SARS-COV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection. published in MedRXive on Sept 14, 2021; MS ID#: MEDRXIV/2021/262725; https://www.medrxiv.org/content/10.1101/2021.09.07.21262725v1
We found that SARS-CoV‑2 delta mutant antibody neutralisation was reduced compared to the Wuhan wild type (wt), as assessed in a novel inhibition assay with a finger prick blood drop. Strong T cell responses were present against wt and mutant SARS-CoV2 variants, including the delta (B.1.617.2) strain, in fully vaccinated individuals, whereas they were weaker 1 year after natural infection. Hence, immune responses after vaccination are stronger compared to those after naturally occurring infection, pointing out the need of vaccines to overcome the pandemic.